ResMed Inc. vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.15 (market cap $3.80B). The key difference: ResMed Inc. is far larger — about 8.4× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and ResMed Inc. pays a 1.16% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| RMD | VNQI | |
|---|---|---|
Market Cap | $31.89B | $3.80B |
Volume | 618,314 | 277,049 |
Sector | Health | — |
52-Week High | $277.88 | $50.76 |
52-Week Low | $182.82 | $41.81 |
Typical Hold Time | 51 Days | 95 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
VNQI trades at $41.82, showing minimal daily movement with a 0.02% gain. Technical indicators signal bearish momentum as moving averages show unanimous selling pressure, though oscillators remain neutral. Recent news highlights a significant 45.9% drop in short interest in September 2026, while the fund continues to offer competitive advantages including exposure to international real estate markets across 30+ countries and a higher dividend yield compared to domestic alternatives.
The ETF faces headwinds from global real estate market volatility but maintains structural strengths through diversification and cost efficiency. Key risks include international economic sensitivity and currency fluctuations, while the reduced short interest suggests some investor confidence. Long-term appeal lies in international real estate exposure and income generation potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →